Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

‘No One-Size-Fits-All’ First-Line Treatment for Mantle Cell Lymphoma

July 14th 2021

Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.

When MCL Relapses Early, Consider Different Treatment Options

July 13th 2021

Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.

FDA Fast Tracks Drug to Treat MCL

July 2nd 2021

The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.

MCL Treatment: Differences Exist Between Trial-Based Recommendations and Real-World Care

June 29th 2021

Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.

Treatment Intensity After Deferring Initial Therapy May Not Indicate Improved Survival in Mantle Cell Lymphoma

May 28th 2021

Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.

Tecartus May Contribute to Long-Term Responses in Relapsed/Refractory Mantle Cell Lymphoma

May 5th 2021

Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.

First-Line Immunochemotherapy With Maintenance Therapy May Lead to Long-Term Remission in Mantle Cell Lymphoma

April 9th 2021

A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.

Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma

April 8th 2021

Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.

Patients With Previously Treated Multiple B-Cell Malignancies Respond Safely to Next-Generation BTK Inhibitor

April 6th 2021

Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.

Sponsored Content: Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

March 17th 2021

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Minimal Residual Disease Positivity After Treatment Could Lead to Worse Outcomes in MCL

February 16th 2021

A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.

The Top 5 News and Updates in Mantle Cell Lymphoma That Patients May Have Missed in 2020

December 29th 2020

A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.

Gazyva with Chemotherapy May Eliminate Disease in Bone Marrow Before Transplantation in Mantle Cell Lymphoma

November 16th 2020

This treatment, which included dexamethasone, high-dose cytarabine and cisplatin, was well tolerated in this patient population, although longer-term follow-up is needed to see if the benefit persists.

Closer to a Cure for Mantle Cell Lymphoma

September 25th 2020

Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).

Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients

September 22nd 2020

Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.

Cirmtuzumab Combinations Show Potential in Treatment of Mantle Cell Lymphoma

September 9th 2020

Dr. Lori A. Leslie discuses the potential of combination therapies with the emerging agent cirmtuzumab for patients with mantle cell lymphoma.

Bendamustine-Rituxan Combination Shows Promise in Frontline Treatment of Most Patients with Mantle Cell Lymphoma

September 2nd 2020

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.

The Latest News and Updates in Mantle Cell Lymphoma

August 11th 2020

A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.

Options for Patients with Mantle Cell Lymphoma Are 'Exploding', Expert Says

August 10th 2020

“It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie.

Approval of First CAR T-Cell Therapy for Relapsed/Refractory MCL to Change How Patients are Treated 'Forever and for the Better'

August 4th 2020

“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.

5 Recent FDA Approvals Patients with Cancer May Have Missed

August 3rd 2020

The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

No 'One Great Answer' When it Comes to What Rights Those Affected By Cancer Have When Returning to Work Amid COVID-19

July 29th 2020

There are some job protected options for patients with cancer, survivors and caregivers to consider when it comes to returning to work during the COVID-19 pandemic. But, as one cancer rights attorney notes, there are many challenges to those options.

FDA Approves First CAR T-Cell Therapy, Tecartus, for Relapsed or Refractory Mantle Cell Lymphoma

July 24th 2020

The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed that the CAR T-cell therapy induced a response in 87% of patients.

Several Leading Cancer Organizations Urge US to Reconsider Withdrawing from the World Health Organization

July 22nd 2020

Patients with cancer have been encouraged to reach out to legislators and share their personal stories and advocate for why they think continued funding is important to further cancer research.

Expert Advises Genetic Profiling in MCL Can Be a Useful Tool in Treating The Disease

July 7th 2020

“We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable,” said Dr. Jia Ruan.

Analysis Identifies Predictors of Survival in Older Patients With Mantle Cell Lymphoma

July 7th 2020

“It is important to note that the data predates the widespread use of BTK inhibitors and even cellular therapies such as CAR T-cell therapy, specifically,” Dr. Reem Karmali said in an interview. “And so, it doesn't reliably reflect the potential advancements and survival that we've been able to achieve with these novel targeted therapies.”

Cancer Survivors Reflect on a Day of Celebration and Inspiration

June 8th 2020

To commemorate National Cancer Survivors Day on June 7, CURE® invited its readers to share their encouraging stories of survival.

Pharmacologic Data Supports Use of Novel CAR T-Cell Therapy in Patients With Poor-Risk Mantle Cell Lymphoma

May 31st 2020

“Altogether, this pharmacological data supports the concept of CAR T-cell therapy being able to overcome MCL disease with poor risk factors,” said lead study author Dr. Luhua (Michael) Wang.

Revlimid and Rituxan Combo 'Another Potential Option' For Patients With Mantle Cell Lymphoma

May 30th 2020

“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.

In the 'Midst of a Real Shakeup': Perspective on Next Few Years of Mantle Cell Lymphoma Treatments

May 27th 2020

“I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” said Dr. Ian Flinn in an interview with CURE®.